Dose: 0.014 mg/kg
Single Dose: 0.014 (0.014)
Frequency: 12 hourly
Route: PO
Instructions: -

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose: 0.025 mg/kg
Single Dose: 0.025 (0.025)
Frequency: 12 hourly
Route: Oral
Instructions: -

. It is of Synthetic origin and belongs to Piperidyl Benzo Pyridine. It belongs to H1-antagonist pharmacological group on the basis of mechanism of action. The Molecular Weight of Azatadine (Maleate) is 522.60. Its pKa is 8.4.

Azatadine (Maleate) is contraindicated in conditions like Glucoma,Prostatic hypertrophy,Pyloric disease,Pyloric stenosis,Hypersensitivity,Urinary retention.

The signs and symptoms that are produced after the acute overdosage of Azatadine (Maleate) include Tachycardia, Blurred vision, Drowsiness, Dry mouth, Urinary retention, Confusion.The symptomatic adverse reactions produced by Azatadine (Maleate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Vertigo, Headache, Drowsiness, Nausea, Constipation, Dry mouth, Blurred vision, Dysuria, Mood changes.

Azatadine (Maleate) is primarily indicated in conditions like Allergic pruritis, Allergic rhinitis, Hay fever, Urticaria, Vasomotor rhinitis.

No data regarding the interactions of Azatadine (Maleate) was found.

Drug should not be given to Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

tabs Store in a well closed container, at room temperature, .

Azatadine should be used with caution in bone marrow depression. Patients should observe caution while driving or performing other task requiring alertness because it may cause drowsiness. It should be used with caution in patients with urinary retention, history of bronchial asthma, hyperthyroidism, cardiovascular or liver disease. It should be used with caution in person with acute or chronic respiratory impairment, especially in children. Do not administer azatadine subcutaneously because irritation or lesion may occur.